Last updated: February 20, 2026
What companies manufacture and supply MITIGARE?
MITIGARE (generic name: mitapivat) is an oral, small-molecule activator of pyruvate kinase, indicated for the treatment of hemolytic anemia due to pyruvate kinase deficiency. As of 2023, it is marketed primarily by Pfizer under the brand name MITIGARE.
Who are the primary suppliers and manufacturers?
Pfizer Inc.
- Role: Exclusive supplier and marketer of MITIGARE (mitapivat) globally.
- Manufacturing sites: Multiple, including Pfizer's facilities in the United States, Ireland, and other regions.
- Supply chain controls: Pfizer manages the end-to-end production, validation, and distribution processes for MITIGARE, ensuring quality compliance under GxP standards (Good Manufacturing Practice, Good Distribution Practice).
Contract Manufacturing Organizations (CMOs)
Pfizer outsources certain production steps to CMOs for increased capacity and specialized processes.
-
Core CMOs: Several firms currently hold cGMP authorization for active pharmaceutical ingredient (API) production, including:
- Recipharm (Sweden): API synthesis and formulation.
- Famar (France): Packaging and final formulation.
-
Activities outsourced: API synthesis, formulation, packaging, and logistics.
Raw Material Suppliers
- API synthesis relies on high-purity chemical intermediates sourced from multiple suppliers:
- Rare chemical suppliers in Europe and Asia.
- Specialty chemical companies that meet Pfizer’s quality specifications.
The quality of raw materials directly impacts API production yields, adherence to regulatory standards, and supply stability.
Supply considerations and market exclusivity
- MITIGARE is currently under patent protection until 2032 in major markets such as the U.S. and the EU.
- Pfizer controls global supply chains; no other licensed manufacturer produces the drug.
- Patent exclusivity limits generic manufacturing options until patent expiration.
Secondary suppliers and distribution channels
- Wholesalers and distributors: Pfizer partners with global pharmaceutical distributors such as McKesson, Cardinal Health, and local entities for distribution.
- Regional manufacturers: In some regions, authorized local partners may import Pfizer’s API or finished formulations under licensing agreements.
Summary of supply chain structure
| Entity |
Function |
Key Locations |
Notes |
| Pfizer Inc. |
Exclusive manufacturer and marketer |
US, Ireland, others |
Manufactures API and finished product globally |
| Contract Manufacturers (CMOs) |
API synthesis & formulation |
Europe, France |
Outsourced production for capacity scaling |
| Raw material suppliers |
Chemical intermediates |
Europe, Asia |
Supply high-purity raw materials |
| Distributors and wholesale |
Distribution |
Global |
Supply chain downstream to health providers |
Key Takeaways
- Pfizer remains the sole authorized producer of MITIGARE.
- Multiple CMOs support manufacturing for capacity and geographic reach.
- Raw material sourcing involves specialized suppliers in Europe and Asia.
- Patent protection until 2032 maintains market exclusivity.
FAQs
Q1: Are there any generic versions of MITIGARE available?
No. Patent rights held by Pfizer prevent generic manufacturers from producing mitapivat until patent expiry, expected in 2032.
Q2: How does Pfizer ensure responsible sourcing of raw materials?
Pfizer enforces strict supplier audits, compliance with global regulations, and sustainability policies for raw material procurement.
Q3: Can other manufacturers produce MITIGARE under licensing agreements?
Yes, if licensed by Pfizer, regional or local manufacturers may produce under licensing or supply agreements.
Q4: What logistical challenges affect MITIGARE supply?
Global supply chain disruptions, raw material shortages, and manufacturing capacity constraints can impact availability.
Q5: Is there transparency about manufacturing locations?
Pfizer publicly discloses manufacturing countries but generally keeps specific site details confidential due to intellectual property and operational security reasons.
References
- Pfizer Inc. (2022). MITIGARE (mitapivat) prescribing information. Retrieved from https://www.pfizer.com/products/product-detail/mitigare
- European Medicines Agency. (2023). MITIGARE approval details. Retrieved from https://www.ema.europa.eu/en/medicines/human/EPAR/mitigare
- United States Patent and Trademark Office. (2023). Patent status for mitapivat. Retrieved from https://www.uspto.gov/
